06/18/2025
Prasinezumab, which is at the leading-edge of medications being developed to slow the progression of Parkinson’s disease, is moving into Phase III testing. If successful, the trial’s findings ultimately could be used to request approval from regulatory agencies, like the FDA, for widespread use.
The hallmark of Parkinson’s in the brain is the build-up of proteins that destroy dopamine neurons. Scientists hope the drug, developed by Roche, could bind to those toxic proteins and limit their damaging effects on the brain. Breaking this cycle could stop the damage that causes Parkinson’s symptoms to get progressively worse over time — and even halt the disease entirely, so that symptoms could be minimized or potentially never emerge.
A phase III trial tests a drug in a large number of people over the course of months to years in order to gauge the drug’s effectiveness, side effects and safety. Details on the prasinezumab trial size and length have yet to be announced. Read more: https://bit.ly/3I2FM7i